A blog about chemistry, drug development, science, and technology
Seems Germany is not impressed with Acomplia from Sanofi-Aventis and it will be on there non-reimbursable drugs list.
PharmaLive: Sanofi-Aventis Intends to Contest in Court the Decision to Classify Acomplia Among Non-reimbursable Drugs in Germany
What this basically means from my understanding is that the drug is considered a “comfort drug” and will not be covered by German health insurance. this means the drug will not be prescribed as widely as it would otherwise. Sanofi has stated they feel the classification is unjustified and will contest the decision.
On another note, I have read that the drug, if approved in the US will likely be called Zimulti.
Other Resources:
Acomplia Report - Acomplia Turned Down for Coverage by German Health Insurance
Technorati Tags: Acomplia, Rimonabant, Sanofi, Sanofi-Aventis
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 1.363 seconds